Pfizer, Inc. (PFE) PT Set at $37.00 by BMO Capital Markets
Pfizer, Inc. (NYSE:PFE) received a $37.00 price objective from equities research analysts at BMO Capital Markets in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price indicates a potential upside of 1.65% from the company’s current price.
Several other equities analysts also recently weighed in on PFE. Berenberg Bank reissued a “hold” rating and issued a $36.00 price target (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $38.21.
Pfizer (NYSE PFE) opened at 36.40 on Tuesday. The company has a market cap of $216.48 billion, a price-to-earnings ratio of 26.63 and a beta of 1.00. The firm’s 50-day moving average is $34.92 and its 200 day moving average is $33.71. Pfizer has a 52-week low of $29.83 and a 52-week high of $36.51.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.64 earnings per share. On average, equities research analysts predict that Pfizer will post $2.56 EPS for the current fiscal year.
In related news, CEO Ian C. Read sold 197,168 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Lowe FS increased its position in shares of Pfizer by 54.9% during the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock valued at $23,000 after acquiring an additional 260 shares during the last quarter. Taylor Wealth Management Partners increased its position in shares of Pfizer by 4.3% during the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 105 shares during the last quarter. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 137 shares during the last quarter. Nelson Roberts Investment Advisors LLC increased its position in shares of Pfizer by 6.7% during the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 189 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the second quarter valued at about $102,000. Hedge funds and other institutional investors own 68.99% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.